Novo Nordisk is investing 550 million Danish kroner (EUR 75 million; $100 million) in a new research and development facility in Bagsværd, Denmark. This purification plant will expand the company’s capacity to produce active pharmaceutical ingredients (APIs) for a growing number of diabetes drugs under development.

The pilot plant will be fully operational by late 2016. It will be run by CMC Supply (Chemistry, Manufacturing and Control Supply); a unit within Novo Nordisk R&D. CMC Supply develops, produces, and formulates all new protein and peptide processes in Novo Nordisk.
The project will create up to 35 new jobs over a two-year period in addition to the 100 new employees CMC Supply will hire in Denmark in 2014.

• Novo Nordisk A/S, Bagsværd, Denmark